A PHASE III, OPEN LABEL TRIAL, SINGLE ARM, MULTI-CENTER, TRIAL TO ASSESS THE SAFETY AND IMMUNOGENICITY OF A BOOSTER VACCINATION WITH A RECOMBINANT PROTEIN RBD FUSION HETERODIMER CANDIDATE (PHH-1V) AGAINST SARS-COV-2, IN ADULTS VACCINATED AGAINST COVID-19
Latest Information Update: 16 Mar 2023
At a glance
- Drugs PHH-1V (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Registrational
- Sponsors LABORATORIOS HIPRA
Most Recent Events
- 14 Mar 2023 Status changed from recruiting to completed.
- 03 Feb 2022 New trial record